
Litron Laboratories (AKA: Litron Laboratories Ltd) Profile last edited on: 10/31/2023
CAGE: 0WSM9
UEI: LJH7LE9AUHL5
Business Identifier: State-of-the-art flow cytometric methods Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 25
County: Monroe
Congr. District: 25
County: Monroe
Public Profile
In business since 1976 and active in the SBIR arena from the first few years of the program's functioning, Litron provides critical data to pharmaceutical, medical device, government and contract research organizations worldwide. Organized around DNA damage and other toxic effects, principals of the firm develop state-of-the-art flow cytometric methods to solve challenging problems for the toxicology industry. With an emphasis on safety testing of new compounds and devices, Litron offers genetic toxicology service. Current research includes an developing a flow cytometric method for scoring in vitro micronuclei and measuring micronuclei in human peripheral blood. The firm is a genetic toxicology research and testing company focusing on the safety testing of drugs and medical devices. Patented MicroFlow® kits (for research use only) use a few drops of blood from a mouse, rat or human for rapid accurate analysis of DNA damage (which is related to long-term cancer risk). These kits offer both speed and objectivity using high speed flow cytometry.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
15-19Revenue Range
1.5M-2MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
25-49Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
1742206802 | 2 | NIH | $295,735 | |
Project Title: Development of a Comprehensive Hen's Egg Model for Genotoxicity Testing | ||||
2023 | 2 | NIH | $1,832,396 | |
Project Title: High Throughput Screen and High Information Follow-Up Tests for Genotoxicants | ||||
2023 | 1 | NIH | $230,278 | |
Project Title: Modeling the Responsiveness of Sensitive Populations to Genotoxic Agents Using DNA Repair Inhibitors | ||||
2020 | 1 | NIH | $176,622 | |
Project Title: Development of Rat Liver 3d Organoid Methods to Address Genotoxicity Screening | ||||
2020 | 2 | NIH | $1,135,816 | |
Project Title: Next Generation Testing Strategies for Assessment of Genotoxicity |
Key People / Management
Carol Tometsko -- President
Erica Briggs
Stephen D Dertinger
Francis G Murante
Andrew M Tometsko -- Director of Business Development
Dorothea K Torous
Erica Briggs
Stephen D Dertinger
Francis G Murante
Andrew M Tometsko -- Director of Business Development
Dorothea K Torous
Company News
There are no news available.